CliffBio
small molecule

MARQIBO KIT

VINCRISTINE SULFATE

Loss of exclusivity—loss of exclusivity
CompanyAcrotech Biopharma →See this company's full patent-cliff portfolio

Drug detail

Brand nameMARQIBO KIT
Active ingredientVINCRISTINE SULFATE
Strength5MG/5ML (1MG/ML)
Dosage formINJECTABLE, LIPOSOMAL
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalAugust 2012
Marketing statusDISCN

More from Acrotech Biopharma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

MARQIBO KIT patent cliff — loss of exclusivity — | CliffBio